Matinas BioPharma Holdings Inc. [AMEX: MTNB] price surged by 18.18 percent to reach at $0.22. The company report on February 1, 2021 that Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®.
– LYPDISO™ demonstrated a statistically significant 46% relative percent increase in EPA change from baseline over Vascepa® –.
– LYPDISO™ demonstrated a 39% relative difference in response over Vascepa in TG reduction –.
A sum of 11548648 shares traded at recent session while its average daily volume was at 5.72M shares. Matinas BioPharma Holdings Inc. shares reached a high of $1.45 and dropped to a low of $1.19 until finishing in the latest session at $1.43.
Guru’s Opinion on Matinas BioPharma Holdings Inc. [MTNB]:
Piper Sandler have made an estimate for Matinas BioPharma Holdings Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 26, 2020. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on January 27, 2020, representing the official price target for Matinas BioPharma Holdings Inc. stock.
The Average True Range (ATR) for Matinas BioPharma Holdings Inc. is set at 0.20, with the Price to Sales ratio for MTNB stock in the period of the last 12 months amounting to 3025.09. The Price to Book ratio for the last quarter was 4.47, with the Price to Cash per share for the same quarter was set at 0.31.
MTNB Stock Performance Analysis:
Matinas BioPharma Holdings Inc. [MTNB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 48.96. With this latest performance, MTNB shares dropped by -8.92% in over the last four-week period, additionally plugging by 60.85% over the last 6 months – not to mention a rise of 5.15% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MTNB stock in for the last two-week period is set at 52.71, with the RSI for the last a single of trading hit 53.89, and the three-weeks RSI is set at 53.16 for Matinas BioPharma Holdings Inc. [MTNB]. The present Moving Average for the last 50 days of trading for this stock 1.2813, while it was recorded at 1.2180 for the last single week of trading, and 0.9282 for the last 200 days.
Insight into Matinas BioPharma Holdings Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Matinas BioPharma Holdings Inc. [MTNB] shares currently have an operating margin of -21067.38. Matinas BioPharma Holdings Inc.’s Net Margin is presently recorded at -19343.35.
Return on Total Capital for MTNB is now -70.32, given the latest momentum, and Return on Invested Capital for the company is -65.49. Return on Equity for this stock declined to -70.63, with Return on Assets sitting at -57.73. When it comes to the capital structure of this company, Matinas BioPharma Holdings Inc. [MTNB] has a Total Debt to Total Equity ratio set at 12.79. Additionally, MTNB Total Debt to Total Capital is recorded at 11.34, with Total Debt to Total Assets ending up at 10.51. Long-Term Debt to Equity for the company is recorded at 12.90, with the Long-Term Debt to Total Capital now at 10.06.
Reflecting on the efficiency of the workforce at the company, Matinas BioPharma Holdings Inc. [MTNB] managed to generate an average of -$827,269 per employee.Matinas BioPharma Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 23.00 and a Current Ratio set at 23.00.
MTNB Stock EPS
With the latest financial reports released by the company, Matinas BioPharma Holdings Inc. posted -0.04/share EPS, while the average EPS was predicted by analysts to be reported at -0.03/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -33.30%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MTNB.
Matinas BioPharma Holdings Inc. [MTNB] Insider Position Details
There are presently around $65 million, or 23.40% of MTNB stock, in the hands of institutional investors. The top three institutional holders of MTNB stocks are: BOXER CAPITAL, LLC with ownership of 11,478,634, which is approximately 0% of the company’s market cap and around 0.80% of the total institutional ownership; VIVO CAPITAL, LLC, holding 11,279,323 shares of the stock with an approximate value of $16.13 million in MTNB stocks shares; and VANGUARD GROUP INC, currently with $10.9 million in MTNB stock with ownership of nearly 0% of the company’s market capitalization.
Positions in Matinas BioPharma Holdings Inc. stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 22 institutional holders increased their position in Matinas BioPharma Holdings Inc. [AMEX:MTNB] by around 1,792,554 shares. Additionally, 19 investors decreased positions by around 3,907,476 shares, while 33 investors held positions by with 39,590,572 shares. The mentioned changes placed institutional holdings at 45,290,602 shares, according to the latest SEC report filing. MTNB stock had 10 new institutional investments in for a total of 145,489 shares, while 9 institutional investors sold positions of 2,895,798 shares during the same period.